Today I stumbled across a page where financial guru Michael Robinson talks about the “Cryogenic Blood Revolution”. And how a $6 Californian company has the only FDA approved technology on the planet to capitalize on it.
Is it legit? The Cryogenic Blood Revolution isn’t a scam, it’s a free report you get when you purchase a subscription to Nova-X Report. And it’s (somewhat) based on a real technology. One that was developed by a legitimate company in the blood transfusion space.
Let’s take a closer look at what this is all about, and whether or not it’s actually worthwhile, so you know what to expect before joining.
What’s The Cryogenic Blood Revolution About?
According to Michael Robinson, cryogenic blood is a radical technology that is going to save over 2 million lives. And give “superhuman healing powers” to American soldiers, dying cancer patients, and even infants.
In other words, a game changing technology. One that is going to disrupt the medical industry like never before in history.
And he says there’s only one company with this FDA (Food and Drug Administration) approved technology. And that if you buy shares of that company, you could make 10,000% gains when this “revolution” kicks off.
What company is he talking about?
Well, he doesn’t say specifically on the page. Because he wants you to buy a subscription to his financial newsletter called Nova-X Report for $39. And then he’ll reveal that company as part of a bonus report.
But I did some digging…
We know it’s a $6 stock and that it’s a company based in California, that deals with blood related technology, and has an FDA approval.
And after doing some research, I’m confident it’s a company called Cerus Corporation. Who has basically developed an FDA approved technology that makes blood transfusions safer, called the INTERCEPT Blood System. Which I learned in this Cerus press release:
Cerus Corporation (Nasdaq:CERS) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s pathogen-reduced cryoprecipitate product candidate. The basis of the designation is improved treatment of massive hemorrhage, a life-threatening medical condition.
Ask yourself, what sounds more exciting…
A “pathogen-reduced cryoprecipitate product” or “cryogenic blood”?
I’m confident you chose the latter.
Cryogenic blood is essentially a marketing angle. Which they’ve used because it sounds a heck of a lot sexier than the real, scientific name behind this technology.
Anyway, at the time of writing this (December 17, 2019), it’s less than $6 per share. But who knows what the future holds. At least now you don’t have to buy anything to know what stock he’s referring to. You can view the Cerus stock price on Nasdaq.com.
Who’s Behind Cryogenic Blood?
Michael Robinson is the man that came up with the “cryogenic blood revolution” concept. He’s a 35-year Silicon Valley veteran and financial author for sites like Money Map Press and Money Morning.
He’s was involved in the $160 billion “cloud” computing phenomenon. And he’s worked with the CEOs of Chrysler and GM during the robotic revolution that saved the US automotive industry.
So he has a track record of success within the tech industry and has successfully helped men and women from all over the world profit from it.
He’s best known for being the creator of financial subscriptions like Nova-X Report and Radical Technology Profits, which you can find through the Money Map Press website.
What’s Money Map Press?
It’s a financial publishing site that brings together experts from different backgrounds and expertise, to deliver information about investing.
For example, on the Money Map Press website, you’ll find other financial gurus like Tom Gentile who created Money Calendar Pro, Andrew Keene who created The 1450 Club, and D.R Barton who came up with Federal Rent Checks.
And of course, Michael Robinson, who came up with the cryogenic blood concept as a way to promote his Nova-X Report subscription.
How Does It Work?
As I said earlier, the whole cryogenic blood revolution thing is essentially a marketing gimmick. There is truth to what Michael Robinson is saying, but that term is something that he (and the Money Map Press marketing team) made up.
It’s really about investing in a stock of a California based company called Cerus Corporation. Which is an innovator in the blood transfusion space.
And in order to get access to that information, you need to buy the Nova-X Report, since the Cryogenic Blood Revolution is just a bonus that comes with a $39 per year Nova-X Report subscription.
What’s Nova-X Report all about?
Nova-X Report is a 12 month financial newsletter subscription presented by Michael Robinson, who shares his recommended tech-driven investment opportunities.
The newsletter focusses on what he believes are seven of the fastest-moving technologies in the world, responsible for $7 Trillion in tech-driven wealth. Which is something he refers to as The Opportunity Matrix.
How much does it cost?
A subscription to Nova-X Report costs $39 per year. Or you can get the VIP upgrade, which costs $79 per year.
Here’s a breakdown of what you get as a member:
- 12 monthly Editions of Nova-X Report: monthly newsletters delivered by email and accessible through the members area.
- Instant Profit Alerts: alerts of when to buy, sell, and hold Michael’s stock picks.
- Weekly Intelligence Briefings: weekly analysis on the current market and opportunities to invest in different stocks.
- Nova-X Report Video Briefings: breaking tips on what is happening in the market right now.
- 24/7 Access to the Nova-X Report Members-Only Website: Everything you get as a member is archived in this members only site.
- The Nova-X Report Premium Concierge Service: customer support (lol).
In addition to the above member benefits, you also get four bonus reports that is only available to those who buy through the Cryogenic Blood sales page.
Here’s an overview of the four bonus reports:
- The $6 Company Riding the Cryogenic Blood Revolution
- The $12.3 Billion Medical Tech Play That Could Make You Million
- The Silicon Valley Firm at the Center of the $55 Billion Automation Revolution
- Profiting from “Secret” Military Spending
Is Cryogenic Blood a Scam?
No, I don’t believe Cryogenic Blood Revolution is a scam.
It is (more or less) based on a real technology developed by a real company that could stand to make huge profits in the future. And by investing in shares of their stock as Michael Robinson suggests, you could too.
But the term “cryogenic blood” isn’t a real thing in and of itself. It’s a marketing angle to sell a subscription to the Nova-X Report. And it works because it sounds a lot more exciting than the real product name.
Go ahead and read the Cerus press release I linked to earlier. I think you will quickly find that (within about 5 seconds of reading it) that the sales letter Michael created is a heck of a lot more exciting!
He makes it sound like “superhuman” blood. When it’s really a pathogen-reduced cryoprecipitate product that makes blood transfusions safer.
Sites like Money Map Press have clever marketing teams at their disposal. They know what sells and how to make virtually anything sound like the next big thing.
Don’t get me wrong, it looks like an amazing innovation that really could change the world, so in that respect it is exciting. And it could be a great investment opportunity as a result.
So I wouldn’t call this a scam, but I would say you should take the sales copy with a grain of salt. A big one, lol.
- Michael Robinson is an expert in tech investing and shares his insights with members of his subscription service, Nova-X Report.
- The “cryogenic blood” stock he recommends is legit and potentially worth checking out.
- Nova-X Report only costs $39 per year.
- There’s a 60 day money back guarantee in place.
- I don’t like how this subscription is marketed, I think Money Map Press should be more upfront as to what it’s really about.
- Some of the claims (like suggesting you can make 10,000% profit) are not what the average person should expect going into this.
Summing It Up
Overall I feel that the Cryogenic Blood Revolution could be something worth looking into further, if investing in medical related technology interests you.
And as a member of Nova-X Report, which you have to become in order to get access to the Cryogenic Blood Revolution bonus report, you will no doubt learn some valuable insights from Michael Robinson.
For $39 per year you are getting access to a lot of great information which could potentially help you become a better investor. And which could even lead to some serious profits over time.
Either way, I wouldn’t expect to sign up and get rich overnight.
Just as there is upside potential with the stocks he recommends, there’s also downside potential. Any type of investing is risky, because nobody can predict the future. So it is wise to only invest what you can afford to lose.